Congress moves to strip patents from high-priced drugs, unleashing generics

What it does

This bill directs the Secretary of Health and Human Services to identify brand-name drugs with 'excessive' prices by comparing U.S. prices to those in Canada, the UK, Germany, France, and Japan, and to consider factors like patient population size, therapeutic value, and R&D costs. When a drug is deemed excessively priced, the government must waive patent protections and grant open licenses allowing generic and biosimilar manufacturers to produce the drug, paying only a reasonable royalty to the original patent holder. The bill also requires drug manufacturers to report detailed pricing and R&D data annually, establishes a public database of excessive-price determinations, and imposes civil penalties on manufacturers who fail to report or provide false information.

Why we flagged it

The bill's core function is to empower the Secretary to identify excessively priced drugs and strip patent protections to enable generic/biosimilar competition. This is fundamentally a price-control and intellectual-property-waiver mechanism, not merely a transparency or reporting measure.

What the text implies

• The bill grants the Secretary broad discretion to define 'excessive price' using multiple subjective factors (therapeutic value, patient population size, cumulative global revenues, etc.), creating potential for inconsistent or politically influenced determinations without explicit appeal or judicial review standards.
• Waiving patent exclusivity and granting open licenses may reduce incentives for pharmaceutical R&D investment in future drugs, particularly for rare diseases or high-risk therapeutic areas where patient populations are small and development costs are high.

The full analysis lists 5 implications of this text.

Who stands to gain

generic drug manufacturers; biosimilar manufacturers; pharmacy benefit managers (PBMs)